Becker's Healthcare June 21, 2024
Johnson & Johnson has completed its $850 million acquisition of Proteologix, a biologics company that specializes in developing treatments for immune-mediated diseases, it announced June 21.
While the acquisition allows the pharmaceutical giant to expand its immune-mediated disease pipeline, the acquisition of Proteologix will also broaden Johnson & Johnson’s atopic dermatitis treatment offerings.
“The Proteologix team has developed a promising early pipeline of bispecific antibodies that are a strong complement and strategic fit for our...
Today's Sponsors
Today's Sponsor